Journal for ImmunoTherapy of Cancer (Dec 2022)

Activated B cells suppress T-cell function through metabolic competition

  • Li Li,
  • Michael Green,
  • Fang Wang,
  • Ye Li,
  • Jennifer Wargo,
  • Marina Konopleva,
  • Elizabeth J Shpall,
  • Rafet Basar,
  • May Daher,
  • Ana Karen Nunez Cortes,
  • Hila Shaim,
  • Natalia Baran,
  • Ken Chen,
  • Luis Muniz-Feliciano,
  • Nobuhiko Imahashi,
  • Yuefan Huang,
  • Pinaki Prosad Banerjee,
  • Junjun Lu,
  • Nadima Uprety,
  • Emily Ensley,
  • Tamara J Laskowski,
  • Judy S Moyes,
  • Mayela Mendt,
  • Lucila N Kerbauy,
  • Mayra Shanley,
  • Francesca Lorraine Wei Inng Lim,
  • Katayoun Rezvani

DOI
https://doi.org/10.1136/jitc-2022-005644
Journal volume & issue
Vol. 10, no. 12

Abstract

Read online

Background B cells play a pivotal role in regulating the immune response. The induction of B cell-mediated immunosuppressive function requires B cell activating signals. However, the mechanisms by which activated B cells mediate T-cell suppression are not fully understood.Methods We investigated the potential contribution of metabolic activity of activated B cells to T-cell suppression by performing in vitro experiments and by analyzing clinical samples using mass cytometry and single-cell RNA sequencing.Results Here we show that following activation, B cells acquire an immunoregulatory phenotype and promote T-cell suppression by metabolic competition. Activated B cells induced hypoxia in T cells in a cell–cell contact dependent manner by consuming more oxygen via an increase in their oxidative phosphorylation (OXPHOS). Moreover, activated B cells deprived T cells of glucose and produced lactic acid through their high glycolytic activity. Activated B cells thus inhibited the mammalian target of rapamycin pathway in T cells, resulting in suppression of T-cell cytokine production and proliferation. Finally, we confirmed the presence of tumor-associated B cells with high glycolytic and OXPHOS activities in patients with melanoma, associated with poor response to immune checkpoint blockade therapy.Conclusions We have revealed for the first time the immunomodulatory effects of the metabolic activity of activated B cells and their possible role in suppressing antitumor T-cell responses. These findings add novel insights into immunometabolism and have important implications for cancer immunotherapy.